Armistice Capital

Portfolio · 2

Purple Biotech

Tumor-immune Evasion and Drug Resistance Therapies

Led ★ 1 round $1.2M committed Latest: 2024-09

Xylo Technologies

Minimally Invasive Endosurgical and Imaging Tools

1 round $11.1M committed Latest: 2014-06

Investment activity

Q&A

What is Armistice Capital's primary investment focus by sector?

Armistice Capital primarily focuses on the Health Tech & Life Sciences sector, with all of its known portfolio companies operating in this area.

What type of funding rounds does Armistice Capital typically participate in?

Armistice Capital has participated in PIPE (Private Investment in Public Equity) rounds.

Can you name some of Armistice Capital's portfolio companies?

Armistice Capital's portfolio includes Purple Biotech, which develops tumor-immune evasion and drug resistance therapies.

When did Armistice Capital make its most recent known investment?

Armistice Capital made a new portfolio investment in September 2024.

What is the typical investment range for Armistice Capital?

Armistice Capital's investment range is between $1.24M and $11.1M.

When was Armistice Capital founded?

Armistice Capital was created in May 2019, according to startupim data.